Probity Advisors, Inc. Bio N Tech Se Transaction History
Probity Advisors, Inc.
- $588 Million
- Q3 2025
A detailed history of Probity Advisors, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Probity Advisors, Inc. holds 2,506 shares of BNTX stock, worth $262,703. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,506
Previous 2,371
5.69%
Holding current value
$262,703
Previous $252,000
1.98%
% of portfolio
0.04%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding BNTX
# of Institutions
319Shares Held
40.7MCall Options Held
1.39MPut Options Held
1.52M-
Baillie Gifford & CO7.88MShares$826 Million0.61% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.23MShares$443 Million1.69% of portfolio
-
Primecap Management CO Pasadena, CA4MShares$419 Million0.35% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD3.6MShares$377 Million0.24% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$199 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $25.4B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...